- Home
- VRTX vs HCA Comparison
VRTX vs HCA Comparison
Compare VRTX & HCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRTX | HCA |
|---|---|---|
| Founded | 1989 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Hospital/Nursing Management |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 105.5B |
| IPO Year | 2006 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VRTX | HCA |
|---|---|---|
| Price | $441.30 | $486.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 20 |
| Target Price | ★ $539.69 | $528.00 |
| AVG Volume (30 Days) | ★ 1.2M | 822.9K |
| Earning Date | 05-04-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | ★ 836.54 | 28.77 |
| EPS | 15.32 | ★ 28.33 |
| Revenue | $2,488,652,000.00 | ★ $75,600,000,000.00 |
| Revenue This Year | $10.81 | $5.07 |
| Revenue Next Year | $10.41 | $4.90 |
| P/E Ratio | $28.88 | ★ $17.29 |
| Revenue Growth | ★ 46.20 | 7.08 |
| 52 Week Low | $362.50 | $314.43 |
| 52 Week High | $510.77 | $556.52 |
Technical Indicators
Market Signals| Indicator | VRTX | HCA |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 43.59 |
| Support Level | $427.52 | $461.11 |
| Resistance Level | $442.22 | $519.90 |
| Average True Range (ATR) | 10.82 | 12.40 |
| MACD | 0.78 | 1.70 |
| Stochastic Oscillator | 55.61 | 51.89 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.